Rx Product News (July 2017)
Read about prescription medications featured in July.
: Amneal Biosciences
INDICATION: Amneal Biosciences’ Tepadina (thiotepa) is now available as a 100-mg vial for injection; previously, the drug was available only as a 15-mg vial for injection. Tepadina is indicated to reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation for pediatric patients with class 3 beta-thalassemia.
DOSAGE: Injection: 100 mg/vial and 15 mg/vial
FOR MORE INFORMATION: amneal.com
: Teva Pharmaceutical Industries Ltd
INDICATION: The FDA has approved Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD). Austedo is the first deuterated product approved by the FDA and only the second product approved for the treatment of HD.
DOSAGE: Tablets: 6, 9, and 12 mg
FOR MORE INFORMATION: tevapharm.com
: MT Pharma America
INDICATION: The FDA has approved Radicava (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS); it is the first new ALS therapy approved by the FDA in several years.
DOSAGE: Intravenous infusion: 30 mg/100 mL
FOR MORE INFORMATION: radicava.com
MARKETED BY: Sanofi and Regeneron Pharmaceuticals
INDICATION: The FDA has approved Sanofi and Regeneron’s Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to 1 or more diseasemodifying antirheumatic drugs, such as methotrexate.
DOSAGE: Injection, 150 mg and 200 mg
FOR MORE INFORMATION: kevzara.com